Trovagene Urine-based Cancer Detection Technology Validated

Trovagene, Inc.

announces that results emerging from ongoing clinical studies have confirmed the broad applicability of Trovagene technology across a variety of cancer types, and the successful development of a molecular diagnostic test capable of detecting and quantifying oncogene mutations from a simple urine specimen. The ability to regularly detect and monitor the results of cancer treatment through a non-invasive, systemic sample could significantly help patients who require therapy for recurrent or metastatic cancer. Clinical validation of Trovagene's ultra-sensitive assay procedure has been confirmed initially for detection of the BRAF mutation from cell-free (cf) DNA in urine. The cf-BRAF test will be available as a laboratory developed test (LDT) this quarter, and offered through the company's CLIA lab.